ASCO - malecare.org

From the 2013 Genitourinary Cancers Symposium – An Update of the Abiraterone Acetate (Zytiga) with Prednisone Clinical Trial

At the recent 2013 2013 Genitourinary Cancers Symposium there was an abstract presented that updated data from the COU-AA-302 clinical trial of Abiraterone Acetate (Zytiga) with prednisone. The updated data confirms that Zytiga with prednisone improves overall survival (OS) in men with metastatic castrate resistant prostate cancer (mCRPC) post-docetaxel therapy (chemotherapy)(Lancet Oncol 2012;13:983-92). The trial [...]

By Malecare|2017-10-19T10:50:08-04:00February 25th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Zytiga|0 Comments

From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade

Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not know what is the optimal duration of AB. Looking at this problem, the researchers conducted a randomized study to compare [...]

By Malecare|2013-02-17T10:43:04-05:00February 17th, 2013|adjuvant therapy, Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Radiotherapy, Uncategorized|0 Comments

Two More Provenge Related Abstracts from the 2013 ASCO GU Symposium

More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at changes in circulating tumor cells (CTC) and the second to the onset of the use of opioid painkillers. Abstract #40 [...]

By Malecare|2017-10-19T10:50:08-04:00February 15th, 2013|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, inflammation, Pain, Provenge, Research, Uncategorized, Understanding APC|0 Comments

From the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium – News of Provenge

Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced prostate cancer. In the course of the next few days I will be reviewing a number of these that I [...]

By Malecare|2020-02-04T08:56:36-05:00February 14th, 2013|abiraterone acetate, Advanced Prostate Cancer, ASCO, Bio Chemical Recurrence, Combination Therapy, Drugs & Treatments, Hormone Therapy, Research, Uncategorized|0 Comments

Coming in Early 2013 – A Genetic Test to Predict Which Prostate Cancers Need treatment and Which can be Subject to Active Surveillance

Genomic Health, Inc. has announced they have had positive results from a large clinical validation study of a biopsy-based prostate cancer test designed to predict adverse pathology in men with early prostate cancer. The study, performed in collaboration with prostate cancer researchers at the University of California, San Francisco (UCSF), met its primary endpoint by [...]

By Malecare|2017-10-19T10:50:45-04:00September 22nd, 2012|Advanced Prostate Cancer, ASCO, biomarkers, Drugs & Treatments, General Information, genetics, Prostate Ponderings, Uncategorized, Understanding APC|1 Comment